I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Vanover, Kim E.
92
results:
Search for persons
X
Sorted by: Relevance
Sorted by: Year
?
1
Pharmacological characterization of AC-262536, a novel sele..:
Piu, Fabrice
;
Gardell, Luis R.
;
Son, Thomas
...
The Journal of Steroid Biochemistry and Molecular Biology. 109 (2008) 1-2 - p. 129-137 , 2008
Link:
https://doi.org/10.1016/..
?
2
Identification of novel selective V2 receptor non-peptide a..:
Del Tredici, Andria L.
;
Vanover, Kim E.
;
Knapp, Anne E.
...
Biochemical Pharmacology. 76 (2008) 9 - p. 1134-1141 , 2008
Link:
https://doi.org/10.1016/..
?
3
P2‐032: ITI‐007 (LUMATEPERONE) FOR THE TREATMENT OF AGITATI..:
Satlin, Andrew
;
Vanover, Kim
;
Glass, Steven
...
Alzheimer's & Dementia. 14 (2018) 7S_Part_12 - p. , 2018
Link:
https://doi.org/10.1016/..
?
4
High-throughput screens identify a lipid nanoparticle that ..:
Huayamares, Sebastian G.
;
Lokugamage, Melissa P.
;
Rab, Regina
...
Journal of Controlled Release. 357 (2023) - p. 394-403 , 2023
Link:
https://doi.org/10.1016/..
?
5
Optimization of lipid nanoparticles for the delivery of neb..:
Lokugamage, Melissa P.
;
Vanover, Daryll
;
Beyersdorf, Jared
...
Nature Biomedical Engineering. 5 (2021) 9 - p. 1059-1068 , 2021
Link:
https://doi.org/10.1038/..
?
6
Pharmacologic profile of ITI-333: a novel molecule for trea..:
Snyder, Gretchen L.
;
Li, Peng
;
Martin, Terry
...
Psychopharmacology. 241 (2024) 7 - p. 1477-1490 , 2024
Link:
https://doi.org/10.1007/..
?
7
Adjunctive lumateperone (ITI‐007) in the treatment of bipol..:
Suppes, Trisha
;
Durgam, Suresh
;
Kozauer, Susan G.
...
Bipolar Disorders. 25 (2023) 6 - p. 478-488 , 2023
Link:
https://doi.org/10.1111/..
?
8
Single doses of a highly selective inhibitor of phosphodies..:
Khalsa, Sahib S.
;
Victor, Teresa A.
;
Kuplicki, Rayus
...
Neuropsychopharmacology. 47 (2022) 10 - p. 1844-1853 , 2022
Link:
https://doi.org/10.1038/..
?
9
Safety and tolerability of lumateperone for the treatment o..:
Kane, John M
;
Durgam, Suresh
;
Satlin, Andrew
...
International Clinical Psychopharmacology. 36 (2021) 5 - p. 244-250 , 2021
Link:
https://doi.org/10.1097/..
?
10
Safety and tolerability of lumateperone 42 mg: An open-labe..:
Correll, Christoph U.
;
Vanover, Kimberly E.
;
Davis, Robert E.
...
Schizophrenia Research. 228 (2021) - p. 198-205 , 2021
Link:
https://doi.org/10.1016/..
?
11
M205. LONG-TERM SAFETY OF LUMATEPERONE (ITI-007): METABOLIC..:
Correll, Christoph
;
Mates, Sharon
;
Huo, Jason
...
Schizophrenia Bulletin. 46 (2020) Supplement_1 - p. S214-S214 , 2020
Link:
https://doi.org/10.1093/..
?
12
186 Results From a 12-Month Open-label Safety Study of Luma..:
Correll, Christoph U.
;
Vanover, Kimberly E
;
Durgam, Suresh
...
CNS Spectrums. 25 (2020) 2 - p. 317-318 , 2020
Link:
https://doi.org/10.1017/..
?
13
185 The Safety and Tolerability of Lumateperone 42 mg for t..:
Kane, John M
;
Vanover, Kimberly E
;
Durgam, Suresh
...
CNS Spectrums. 25 (2020) 2 - p. 316-317 , 2020
Link:
https://doi.org/10.1017/..
?
14
P.468 Cardiometabolic safety of lumateperone (ITI-007): pos..:
Satlin, A.
;
Durgam, S.
;
Vanover, K.E.
...
European Neuropsychopharmacology. 40 (2020) - p. S265-S266 , 2020
Link:
https://doi.org/10.1016/..
?
15
P.446 Efficacy and safety of lumateperone (ITI-007) in the ..:
Durgam, S.
;
Satlin, A.
;
Vanover, K.E.
...
European Neuropsychopharmacology. 40 (2020) - p. S253-S254 , 2020
Link:
https://doi.org/10.1016/..
1-15